Back to search results

Decoy Therapeutics Inc.

STEX25
Active dates:

January 20, 2023 - January 20, 2023
STEX25
View Feature
STEX25 Participation:
January 20, 2023 - June 30, 2024
Company information
Contact

1 Broadway, 14th Floor
Cambridge, MA 02142
United States

http://decoytx.com
Keywords
peptide conjugate, Antiviral, PPMO, PNA, fusion peptide, pan-viral family, SARS-CoV-2, RSV, self-administered drug
Elevator Pitch

Elevator Pitch

Decoy Therapeutics is engineering broad-acting antivirals that target the viruses of today and preemptively protect against the viruses of tomorrow.
Description

Description

The 21st century is experiencing epidemics and pandemics with increasing frequency, and the world needs new tools to combat these diseases. Decoy's platform engineers new pan-viral drugs that address both existing and new zoonotic viral threats. Our lead antiviral nasal spray has demonstrated activity across the sarbecovirus group of coronaviruses as well as all the variants of SARS-CoV-2; expected clinical entry 2023.
Technology Description

Technology Description

We build peptide conjugates with a targeting moiety, a proprietary linker system and antiviral warheads that inhibit conserved viral functions required for viral fitness.